erythropoietin

After high-profile US rejection for roxadustat, Astellas touts its safety in new pooled analysis
Fierce Pharma
Thu, 05/19/22 - 10:32 am
Astellas
roxadustat
FibroGen
ERA
erythropoietin
GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca
Fierce Biotech
Mon, 11/8/21 - 10:47 am
GSK
chronic kidney disease
cliincal trials
FDA
AstraZeneca
anemia
erythropoietin
FibroGen